These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 10382033)
1. [Efficacy of meropenem in the treatment of severe complicated urinary tract infections]. Lopatkin NA; Derevianko II; Khodyreva LA; Kotliarova GA; Kondrat'eva EM; Lavrinova LN Antibiot Khimioter; 1999; 44(3):19-21. PubMed ID: 10382033 [TBL] [Abstract][Full Text] [Related]
2. [Multicenter open randomized trial of meropenem in comparison to ceftazidime and amikacin used in combination in severe hospital infections]. Iakovlev SV; Iakovlev VP; Derevianko II; Kira EF; Antibiot Khimioter; 1998; 43(1):15-23. PubMed ID: 9532327 [TBL] [Abstract][Full Text] [Related]
3. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041 [TBL] [Abstract][Full Text] [Related]
4. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Lee YR; Baker NT Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787 [TBL] [Abstract][Full Text] [Related]
5. [Effectiveness of cefpirome in the treatment of complicated infections of the upper and lower urinary tracts]. Derevianko II; Kotliarova GA; Kondrat'eva EM; Khodyreva LA; Siniukhin VN Antibiot Khimioter; 1996; 41(12):30-3. PubMed ID: 9124983 [TBL] [Abstract][Full Text] [Related]
6. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections]. Hou F; Wu G; Zheng B Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237 [TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections. Hou F; Li J; Wu G; Zheng B; Chen Y; Gu J; Wang H; Huo L; Xue X; Jia C; Yin Y; Tian X; Ren S Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937 [TBL] [Abstract][Full Text] [Related]
8. Meropenem/vaborbactam (Vabomere) for complicated urinary tract infection. Med Lett Drugs Ther; 2018 Jun; 60(1549):103-105. PubMed ID: 29913473 [No Abstract] [Full Text] [Related]
10. [[Multicenter comparative study of meropenem, a new carbapenemic preparation, administered intramuscularly. Treatment of respiratory and urinary infections in hospitalized patients]l]. Lechi A; Montesi G Clin Ter; 1995 Jan; 146(1):31-47. PubMed ID: 7705012 [TBL] [Abstract][Full Text] [Related]
11. Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trial. Wang X; Zhang X; Zong Z; Yu R; Lv X; Xin J; Tong C; Hao Q; Qin Z; Xiong Y; Liu H; Ding G; Hu C; Indian J Med Res; 2013 Dec; 138(6):995-1002. PubMed ID: 24521647 [TBL] [Abstract][Full Text] [Related]
12. [Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract]. Tallarigo C; Comunale L; Baldassarre R; Poletti G Minerva Urol Nefrol; 1995 Sep; 47(3):147-56. PubMed ID: 8815553 [TBL] [Abstract][Full Text] [Related]
13. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus. Embil JM; Soto NE; Melnick DA Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293 [TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of the new carbapenem antibiotic, meropenem, in adult patients with mucoviscidosis]. Samoĭlenko VA; Amelina EL; Chuchalin AG Antibiot Khimioter; 1998; 43(1):24-7. PubMed ID: 9532328 [TBL] [Abstract][Full Text] [Related]
15. [Clinical evaluation of biapenem in various infectious diseases]. Hara K; Baba S; Matsumoto F; Ooishi M; Kawada Y; Arata J; Shinagawa N; Sasaki J; Hayasi K; Sugihara T; Matsuda S Jpn J Antibiot; 1999 Nov; 52(11):629-60. PubMed ID: 10659441 [TBL] [Abstract][Full Text] [Related]
16. [Multicentre study of comparative efficacy of meropenem and combined regimens for empirical antibacterial therapy of severe nosocomial infections: results of clinical and pharmacoeconomic analysis]. Iakovlev SV; Beloborodov VB; Sidorenko SV; Iakovlev VP; Grigor'ev KB; Eliseeva EV; Kon EM; Levit AL; Kostina GV; Kuprenkov AV; Mukhacheva SIu; Saturnov AV; Sergeev IN; Spasov GP; Stakanov AV; Ushakova MA Antibiot Khimioter; 2006; 51(7):15-27. PubMed ID: 18035730 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives]. Yamamoto A; Yamasaki K Nihon Ronen Igakkai Zasshi; 2015; 52(2):153-61. PubMed ID: 25994987 [TBL] [Abstract][Full Text] [Related]
18. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460 [TBL] [Abstract][Full Text] [Related]